Patients with Gout Treated with Conventional Urate-lowering Therapy: Association with Disease Control, Health-related Quality of Life, and Work Productivity

REFERENCES

1. 1.↵
   1. Doghramji PP,
   2. Wortmann RL

   . Hyperuricemia and gout: new concepts in diagnosis and management. Postgrad Med 2012;124:98–109.

   OpenUrlCrossRef
2. 2.↵
   1. Boss GR,
   2. Seegmiller JE

   . Hyperuricemia and gout. Classification, complications and management. N Engl J Med 1979;300:1459–68.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Kannangara DR,
   2. Ramasamy SN,
   3. Indraratna PL,
   4. Stocker SL,
   5. Graham GG,
   6. Jones G,
   7. et al.

   Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients. Arthritis Res Ther 2012;14:R189.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Terkeltaub R,
   2. Edwards NL

   1. Terkeltaub R,
   2. Edwards NL

   . Clinical features and natural course. In: Terkeltaub R, Edwards NL, editors. Gout: diagnosis and management of gouty arthritis and hyperuricemia. Durant, Oklahoma: Professional Communications Inc.; 2013.
5. 5.↵
   1. Zhu Y,
   2. Pandya BJ,
   3. Choi HK

   . Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med 2012;125:679–87.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Khanna PP,
   2. Nuki G,
   3. Bardin T,
   4. Tausche AK,
   5. Forsythe A,
   6. Goren A,
   7. et al.

   Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey. Health Qual Life Outcomes 2012;10:117.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Singh JA,
   2. Sarkin A,
   3. Shieh M,
   4. Khanna D,
   5. Terkeltaub R,
   6. Lee SJ,
   7. et al.

   Health care utilization in patients with gout. Semin Arthritis Rheum 2011;40:501–11.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Smith EU,
   2. Diaz-Torne C,
   3. Perez-Ruiz F,
   4. March LM

   . Epidemiology of gout: an update. Best Pract Res Clin Rheumatol 2010;24:811–27.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Wertheimer A,
   2. Morlock R,
   3. Becker MA

   . A revised estimate of the burden of illness of gout. Curr Ther Res Clin Exp 2013;75:1–4.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Perez-Ruiz F

    . Treating to target: a strategy to cure gout. Rheumatology 2009;48 Suppl 2:ii9–14.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Perez-Ruiz F,
    2. Herrero-Beites AM

    . Evaluation and treatment of gout as a chronic disease. Adv Ther 2012;29:935–46.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Roddy E,
    2. Doherty M

    . Epidemiology of gout. Arthritis Res Ther 2010;12:223.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. DiBonaventura M,
    2. Andrews LM,
    3. Yadao AM,
    4. Kahler KH

    . The effect of gout on health-related quality of life, work productivity, resource use and clinical outcomes among patients with hypertension. Expert Rev Pharmacoecon Outcomes Res 2012;12:821–9.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Khanna PP,
    2. Nuki G,
    3. Bardin T,
    4. Tausche AK,
    5. Forsythe A,
    6. Goren A,
    7. et al.

    Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey. Health Qual Life Outcomes 2012;10:117.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Saseen JJ,
    2. Agashivala N,
    3. Allen RR,
    4. Ghushchyan V,
    5. Yadao AM,
    6. Nair KV

    . Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology 2012;51:2004–12.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Anderson P,
    2. Benford M,
    3. Harris N,
    4. Karavali M,
    5. Piercy J

    . Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin 2008;24:3063–72.

    OpenUrlCrossRefPubMed
17. 17.↵
    EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. EuroQol

    . EQ-5D-3L user guide. Basic information on how to use the EQ-5D-3L instrument. EuroQol Org. [Internet. Accessed February 26, 2016]. Available from: www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ-5D-3L_UserGuide_2015.pdf
19. 19.↵
    1. Fries JF,
    2. Spitz PW,
    3. Young DY

    . The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789–93.

    OpenUrlPubMed
20. 20.↵
    1. Reilly MC,
    2. Zbrozek AS,
    3. Dukes EM

    . The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353–65.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Ace Learning Company

    . HAQ Instructions (ARAMIS Site). Learning Ace Web site. [Internet. Accessed February 26, 2016]. Available from: www.learningace.com/doc/1555309/8f2cb45d41c6d88f5cb786a2b3bc1fa1/haq-instructions-aramis-site-2-14-08
22. 22.↵
    1. Juraschek SP,
    2. Kovell LC,
    3. Miller ER III,
    4. Gelber AC

    . Gout, urate lowering therapy and uric acid levels among US adults. Arthritis Care Res 2014;67:588–92.

    OpenUrl
23. 23.↵
    1. Hamburger M,
    2. Baraf HS,
    3. Adamson TC III,
    4. Basile J,
    5. Bass L,
    6. Cole B,
    7. et al.

    2011 recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med 2011;123 (6 Suppl 1):3–36.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Jordan KM,
    2. Cameron JS,
    3. Snaith M,
    4. Zhang W,
    5. Doherty M,
    6. Seckl J,
    7. et al.

    British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46:1372–4.

    OpenUrlFREE Full Text
25. 25.↵
    1. Khanna D,
    2. Fitzgerald JD,
    3. Khanna PP,
    4. Bae S,
    5. Singh MK,
    6. Neogi T,
    7. et al.

    2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012;64:1431–46.

    OpenUrlCrossRef